Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists a step closer to improved steroid therapy
The study describes a new treatment that may help those unable to produce corticosteroids.


Study reveals corticosterone has fewer side effects

People unable to replace essential steroids in their bodies may soon benefit from improved therapy, thanks to research by the University of Edinburgh.


Published in the journal Science Translational Medicine, the study describes a new treatment that may help those unable to produce corticosteroids.


Scientists say the treatment has fewer side effects and could help provide a safer alternative for treatments like Addison’s disease and congenital adrenal hyperplasia.

Corticosteroids are a class of steroids that help to regulate metabolism and blood pressure. They also help the body to cope with physical stress.

People who suffer from disorders of the adrenal gland need steroid treatment to avoid the risk of potentially fatal illness during physical stress.


Usually, therapy involves replacing one of the steroids they cannot replace - cortisol - with a medication. But this method affects fat tissue and can lead to excessive weight gain, high blood pressure and type 2 diabetes.

In the study, researchers from the University of Edinburgh’s British Heart Foundation (BHF) Centre for Cardiovascular Science examined cortisol - another steroid that is naturally produced by the body.


The team found that, when tested on mice, the effects of corticosterone on fat cells were reduced compared with cortisol. They discovered this was because fat cells have a pump that removes corticosterone. 


Testing the therapy in a small group of Addison’s patients, the team found that corticosterone was just as effective as cortisol. Yet it had reduced effects on fat cells.


“These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison’s disease and congenital adrenal hyperplasia,” said professor Brian Walker, head of the BHF centre for Cardiovascular Science.

The researchers hope that, with further research, their findings may lead to improved therapies for other conditions that respond to steroid treatment, like rheumatoid arthritis and asthma.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.